« Return to News | Clinical Intelligence

Amgen's Xgeva delays prostate cancer metastasis

Wednesday, May 18, 2011 12:22 PM

Results from a phase III trial of Amgen's Xgeva have demonstrated that the drug is able to delay the progression of prostate cancer into the bone, which could increase its market potential, according to Pharma Times.

Data showed that Xgeva (denosumab), which is also marketed as Prolia for the treatment of osteoporosis, significantly improved the median bone metastasis-free survival by 4.2 months, a risk reduction of 15%, compared to placebo.

While no survival benefits were noted, the Xgeva study is reportedly the first randomized trial to show a significant reduction in the risk of bone metastasis for men with prostate cancer.  

 

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.